Author/Authors :
Hishar، H. نويسنده Centre for Diagnostic Nuclear Imaging, Universiti Putra Malaysia , , R.، Price نويسنده Department of Medical Technology & Physics and RAPID PET Technologies, 2Department of Medical Technology & Physics and RAPID PET Technologies, , , Fathinul Fikri، A. S. نويسنده Centre for Diagnostic Nuclear Imaging, Universiti Putra Malaysia , , Eddie Lau، W. F. نويسنده Centre for Cancer Imaging, Molecular Imaging and Targeted Therapeutics Laboratory the Peter MacCallum Cancer Centre , , Assunta، C. نويسنده Department of Nuclear Medicine and PET Centre, San Raffaele Hospital, Milan , , A. J.، Nordin نويسنده Centre for Diagnostic Nuclear Imaging, Universiti Putra Malaysia ,
Abstract :
Development of the positron emission tomography (PET) diagnostic radiopharmaceutical (18F)
fluoro-2-deoxy-D-glucose (18F-FDG) subsequently facilitated the discovery and clinical evaluation of
several new tracers as imaging markers for cancer. While 18F-FDG is a widely employed marker for
enhanced intracellular glycolysis and metabolic function, one of the newer tracers, (18F)-3’-fluoro-3’
deoxythymidine (18F-FLT), has been developed as a biomarker for cell proliferation. In this review, the
potential of 18F-FLT as a biomarker for cancer imaging is discussed.
Keywords :
18F-FLT , 18F-FDG , Positron emission tomography (PET) , Cellular proliferation
